Ernexa Therapeutics (ERNAW) Profit After Tax (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Profit After Tax data on file, last reported at -$5.5 million in Q1 2026.

• Quarterly Profit After Tax rose 32.94% year-over-year to -$5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.3 million (up 75.4% YoY) and the FY2025 annual result came in at -$14.1 million, up 68.34% from the prior year.
• Profit After Tax fell to -$5.5 million in Q1 2026, from -$1.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$1.2 million in Q3 2025 to a low of -$26.6 million in Q3 2024.
• A 5-year average of -$6.5 million and a median of -$5.5 million in 2024 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2024 — Profit After Tax plunged 375.84% — and 2025, when it jumped 95.49%.
• Tracing ERNAW's Profit After Tax over 5 years: stood at -$4.5 million in 2022, then tumbled by 37.07% to -$6.2 million in 2023, then gained by 6.4% to -$5.8 million in 2024, then soared by 73.95% to -$1.5 million in 2025, then plunged by 266.67% to -$5.5 million in 2026.
• The last three Profit After Tax figures came in at -$5.5 million (Q1 2026), -$1.5 million (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.